Table 1.
Parameter (unit) | SLE (n=103) | HC (n=56) |
Age, years; median (IQR) | 47 (26) | 47 (24) |
Female, n (%) | 96 (93.2) | 36 (64.3) |
SLE duration, years; median (IQR) | 12 (12) | na |
SLEDAI, points; median (IQR) | 2.0 (4.0) | na |
SLE history | ||
Skin involvement, n (%) | 88 (85.4) | na |
Arthritis, n (%) | 86 (83.5) | na |
Oral ulcerations, n (%) | 38 (36.9) | na |
Serositis, n (%) | 35 (33.9) | na |
CNS involvement, n (%) | 31 (30.1) | na |
Kidney involvement, n (%) | 23 (22.3) | na |
Clinical parameters | ||
Systolic blood pressure >140 mm Hg, n (%) | 21 (20.4) | nd |
Patients on prednisone, n (%) | 39 (37.9) | na |
Neutrophil count, 109 cells/L; median (IQR) | 3.7 (2.2) | 2.8 (1.1) |
Platelet count, 109 cells/L; median (IQR) | 238 (67.0) | 250 (62.3) |
CRP, mg/L; median (IQR) | 3.1 (2.6) | na |
Urinary protein/creatinine ratio >ULN, n (%) | 8 (7.8) | na |
Serum creatinine, µmol/L; median (IQR) | 67 (20) | na |
Hypocomplementaemia (C3 or C4), n (%) | 57 (55.9) | na |
dsDNA antibody titre, U/mL; median (IQR) | 15 (49) | na |
CNS, central nervous system; CRP, C-reactive protein; dsDNA, double stranded DNA; ESR, erythrocyte sedimentation rate; HC, healthy controls; na, not applicable; nd, not done; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ULN, upper limit of normal.